A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer

Area of Science:

• Oncology
• Urologic Oncology
• Cancer Research

Background:

• Small cell prostate cancer (SCPC) is a rare prostate cancer subtype.
• Optimal staging strategies for SCPC are not well-defined.
• Understanding SCPC incidence and outcomes is critical for patient management.

Purpose of the Study:

• To analyze the incidence and outcomes of SCPC.
• To evaluate the correlation between a binary staging system (limited vs. extensive stage) and prognosis in SCPC patients.
• To identify factors influencing survival in SCPC.

Main Methods:

• Utilized the Surveillance, Epidemiology, and End Results (SEER) database (2004-2016).
• Defined Limited-Stage SCPC (LS-SCPC) as cancer without metastasis.
• Defined Extensive-Stage SCPC (ES-SCPC) as cancer with lymph node or distant metastasis.

Main Results:

• Analyzed 403 SCPC cases, representing 0.056% of all prostate cancer cases.
• LS-SCPC (83 patients) had significantly better overall survival (17 vs. 9 months) and disease-specific survival (25 vs. 10 months) than ES-SCPC (275 patients).
• High prostate-specific antigen (PSA) levels were paradoxically associated with better outcomes in both stages. Chemotherapy improved survival in ES-SCPC (HR 0.52).

Conclusions:

• A binary staging system (LS-SCPC vs. ES-SCPC) effectively correlates with prognosis in small cell prostate cancer.
• This staging mirrors systems used for small cell lung cancer.
• The findings support distinct management strategies based on SCPC stage.